Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial-MedSci.cn

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial

Huang, QD; Wu, XH; Zhu, JQ; Wang, DQ; Yang, JX; Wang, J; Wu, LY; Liu, ZL; Gao, YN; Wang, DB; Lou, G; Yang, HY; Zhou, Q; Kong, BH; Huang, Y; Chen, LP; Li, GL; An, RF; Wang, K; Zhang, Y; Yan, XJ; Lu, X; Wang, L; Tan, T; Dong, J

GYNECOLOGIC ONCOLOGY, 2021; 162 (): S18

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial

科室

工具

服务